Exercise as an add-on treatment in individuals with schizophrenia: Results from a large multicenter randomized controlled trial

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER IRELAND LTD
Autores
MAURUS, Isabel
ROELL, Lukas
LEMBECK, Moritz
PAPAZOVA, Irina
GRESKA, David
MUENZ, Susanne
WAGNER, Elias
CAMPANA, Mattia
SCHWAIGER, Rebecca
SCHNEIDER-AXMANN, Thomas
Citação
PSYCHIATRY RESEARCH, v.328, article ID 115480, 11p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Current treatment methods do not achieve recovery for most individuals with schizophrenia, and symptoms such as negative symptoms and cognitive deficits often persist. Aerobic endurance training has been suggested as a potential add-on treatment targeting both physical and mental health. We performed a large-scale multicenter, rater-blind, parallel-group randomized controlled clinical trial in individuals with stable schizophrenia. Participants underwent a professionally supervised six-month training comprising either aerobic endurance training (AET) or flexibility, strengthening, and balance training (FSBT, control group), follow-up was another six months. The primary endpoint was all-cause discontinuation (ACD); secondary endpoints included effects on psychopathology, cognition, functioning, and cardiovascular risk. In total, 180 participants were randomized. AET was not superior to FSBT in ACD and most secondary outcomes, with dropout rates of 59.55% and 57.14% in the six-month active phase, respectively. However, both groups showed significant improvements in positive, general, and total symptoms, levels of functioning and in cognitive performance. A higher training frequency additionally promoted further memory domains. Participants with higher baseline cognitive abilities were more likely to respond to the interventions. Our results support integrating exercise into schizophrenia treatment, while future studies should aim to develop personalized training recommendations to maximize exercise-induced benefits.
Palavras-chave
Cardiovascular risk, Clinical trial, Lifestyle intervention, Physical activity, Psychosis
URI
https://observatorio.fm.usp.br/handle/OPI/58290
Referências
  1. BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
  2. BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012
  3. Bredin SSD, 2022, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.753117
  4. Chekroud AM, 2021, WORLD PSYCHIATRY, V20, P154, DOI 10.1002/wps.20882
  5. Daumit GL, 2013, NEW ENGL J MED, V368, P1594, DOI 10.1056/NEJMoa1214530
  6. Dauwan M, 2021, J NEUROL, V268, P1222, DOI 10.1007/s00415-019-09493-9
  7. ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766
  8. Falkai P, 2021, EUR ARCH PSY CLIN N, V271, P1201, DOI 10.1007/s00406-021-01282-8
  9. Firth J, 2019, LANCET PSYCHIAT, V6, P675, DOI 10.1016/S2215-0366(19)30132-4
  10. Fusar-Poli P, 2015, SCHIZOPHRENIA BULL, V41, P892, DOI 10.1093/schbul/sbu170
  11. Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb
  12. Green MF, 2016, J CLIN PSYCHIAT, V77, P8, DOI 10.4088/JCP.14074su1c.02
  13. Herring MP, 2012, ARCH INTERN MED, V172, P101, DOI 10.1001/archinternmed.2011.696
  14. Jääskeläinen E, 2013, SCHIZOPHRENIA BULL, V39, P1296, DOI 10.1093/schbul/sbs130
  15. Laursen TM, 2019, SCHIZOPHR RES, V206, P284, DOI 10.1016/j.schres.2018.11.003
  16. Leucht S, 2007, NEUROPSYCHOPHARMACOL, V32, P1903, DOI 10.1038/sj.npp.1301325
  17. Leucht S, 2018, SCHIZOPHR RES, V201, P315, DOI 10.1016/j.schres.2018.05.009
  18. Liberman RP, 2002, INT REV PSYCHIATR, V14, P256, DOI 10.1080/0954026021000016905
  19. Liu-Ambrose T, 2010, ARCH INTERN MED, V170, P170, DOI 10.1001/archinternmed.2009.494
  20. Malchow B, 2015, SCHIZOPHRENIA BULL, V41, P847, DOI 10.1093/schbul/sbv020
  21. Maurus I, 2022, TRANSL PSYCHIAT, V12, DOI 10.1038/s41398-022-02155-x
  22. Maurus I, 2022, SCHIZOPHRENIA-UK, V8, DOI 10.1038/s41537-022-00269-1
  23. Maurus I, 2021, EUR ARCH PSY CLIN N, V271, P315, DOI 10.1007/s00406-020-01175-2
  24. Nielsen RE, 2015, ACTA PSYCHIAT SCAND, V131, P185, DOI 10.1111/acps.12374
  25. Pajonk FG, 2010, ARCH GEN PSYCHIAT, V67, P133, DOI 10.1001/archgenpsychiatry.2009.193
  26. Papiol S, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.131
  27. Rethorst CD, 2017, DEPRESS ANXIETY, V34, P1116, DOI 10.1002/da.22670
  28. Roe D, 2011, SCHIZOPHR RES, V131, P133, DOI 10.1016/j.schres.2011.05.023
  29. RStudio Team, 2020, RStudio. Integrated Development for R
  30. Sabe M, 2020, GEN HOSP PSYCHIAT, V62, P13, DOI 10.1016/j.genhosppsych.2019.11.002
  31. Scheewe TW, 2013, ACTA PSYCHIAT SCAND, V127, P464, DOI 10.1111/acps.12029
  32. Schuch FB, 2016, J AFFECT DISORDERS, V195, P40, DOI 10.1016/j.jad.2016.01.014
  33. Sedgwick O, 2021, PSYCHOL MED, V51, P707, DOI 10.1017/S0033291721000404
  34. Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
  35. Shimada T, 2022, PSYCHIAT RES, V314, DOI 10.1016/j.psychres.2022.114656
  36. Suterwala AM, 2016, J CLIN PSYCHIAT, V77, P1036, DOI 10.4088/JCP.15m10104
  37. Szymczynska P, 2017, J PSYCHIATR RES, V90, P67, DOI 10.1016/j.jpsychires.2017.02.009
  38. van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005
  39. Vancampfort D, 2017, WORLD PSYCHIATRY, V16, P308, DOI 10.1002/wps.20458
  40. Vancampfort D, 2016, GEN HOSP PSYCHIAT, V39, P15, DOI 10.1016/j.genhosppsych.2015.11.008
  41. Villeneuve K, 2010, SCHIZOPHR RES, V121, P266, DOI 10.1016/j.schres.2010.04.003
  42. Vita A, 2018, CURR OPIN PSYCHIATR, V31, P246, DOI 10.1097/YCO.0000000000000407
  43. Wang PW, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00167
  44. Yu Q, 2022, SPORTS MED-OPEN, V8, DOI 10.1186/s40798-022-00529-5

Coleções
Artigos e Materiais de Revistas Científicas - LIM/27